NOVOSEVEN Infusion
Eptacog Alfa
4.8mg (240 KIU)
Novo Nordisk A/S
| Pack size | 4.8mg Vial (Powder) + Solvent Vial + Kit |
|---|---|
| Dispensing mode | POM |
| Source | DENMARK |
| Agent | CITY MEDICAL STORE |
| Retail Price | 16402.00 AED |
Available as:
Indications
NOVOSEVEN Infusion is used for:
Hemophilia, bleeding episodes
Adult Dose
Intravenous
Bleeding episodes in patients with haemophilia
Adult: As activated eptacog alfa: Initially, 90 mcg/kg given via IV bolus over 2-5 min. Additional dose may be given as needed to achieve or maintain haemostasis, initially 2-3 hrly. May adjust dose or dosing interval according to response. May continue therapy for up to 3 wk or more in cases of serious bleeding episodes.
Bleeding episodes due to surgery or invasive procedures in patients with factor VII deficiency
Adult: As activated eptacog alfa: 15-30 mcg/kg 4-6 hrly via IV bolus over 2-5 min until haemostasis is achieved.
Child Dose
Renal Dose
Administration
Contra Indications
Hypersensitivity to the active substance, the excipients, or to mouse, hamster or bovine protein.
Precautions
Patient w/ conditions associated w/ circulating tissue factor (e.g. advanced atherosclerosis, crush injury or septicaemia) due to risk of precipitating thrombosis or disseminated intravascular coagulation. Pregnancy and lactation.
Pregnancy-Lactation
Interactions
Risk of potential DI w/ coagulation factor conc unknown. Avoid simultaneous use of prothrombin complex conc, activated or not. Not recommended to combine rFVIIa & rFXIII.
Adverse Effects
Side effects of Eptacog Alfa :
Nausea, vomiting, skin reactions, fever, headache and changes in BP. Rarely, anaphylaxis.
Mechanism of Action
The mechanism of action includes the binding of factor VIIa to exposed tissue factor. This complex activates factor IX into factor IXa and factor X into factor Xa, leading to the initial conversion of small amounts of prothrombin into thrombin.
Thrombin leads to the activation of platelets and factors V and VIII at the site of injury and to the formation of the haemostatic plug by converting fibrinogen into fibrin.
Note
NOVOSEVEN 4.8mg (240 KIU) Infusion manufactured by Novo Nordisk A/S. Its generic name is Eptacog Alfa. NOVOSEVEN is availble in United Arab Emirates.
Farmaco UAE drug index information on NOVOSEVEN Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.